Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Makharadze T, Quek RGW, Melkadze T, Gogishvili M, Ivanescu C, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Konidaris G, Rietschel P, Gullo G. Makharadze T, et al. Among authors: quek rgw. Cancer. 2023 Jul 15;129(14):2256-2265. doi: 10.1002/cncr.34687. Epub 2023 May 8. Cancer. 2023. PMID: 37151113 Free article. Clinical Trial.
Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy.
Ge W, Wu N, Jalbert JJ, Quek RGW, Liu J, Rietschel P, Pouliot JF, Harnett J, Hsu ML, Feliciano JL. Ge W, et al. Among authors: quek rgw. Cancer Manag Res. 2022 Nov 16;14:3191-3202. doi: 10.2147/CMAR.S376510. eCollection 2022. Cancer Manag Res. 2022. PMID: 36415537 Free PMC article.
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li S, Li Y, Kaul M, Quek RGW, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Makharadze T, et al. Among authors: quek rgw. J Thorac Oncol. 2023 Jun;18(6):755-768. doi: 10.1016/j.jtho.2023.03.008. Epub 2023 Mar 29. J Thorac Oncol. 2023. PMID: 37001859 Free article. Clinical Trial.
Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.
Feliciano JL, McLoone D, Xu Y, Quek RGW, Kuznik A, Pouliot JF, Gullo G, Rietschel P, Guyot P, Konidaris G, Chan K, Keeping S, Wilson FR, Freemantle N. Feliciano JL, et al. Among authors: quek rgw. Front Oncol. 2023 Apr 4;12:1081729. doi: 10.3389/fonc.2022.1081729. eCollection 2022. Front Oncol. 2023. PMID: 37082098 Free PMC article.
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.
Baramidze A, Makharadze T, Gogishvili M, Melkadze T, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Ag McIntyre D, Perez J, Kaul M, Quek RGW, Seebach F, Rietschel P, Pouliot JF. Baramidze A, et al. Among authors: quek rgw. Lung Cancer. 2024 Jul;193:107821. doi: 10.1016/j.lungcan.2024.107821. Epub 2024 May 13. Lung Cancer. 2024. PMID: 38820979 Free article. Clinical Trial.
49 results